Equities Analysts Set Expectations for TMDX Q3 Earnings

TransMedics Group, Inc. (NASDAQ:TMDX) – Equities researchers at William Blair increased their Q3 2026 earnings per share (EPS) estimates for TransMedics Group in a research report issued on Thursday, October 23rd. William Blair analyst R. Daniels now anticipates that the company will post earnings per share of $0.65 for the quarter, up from their prior forecast of $0.64. The consensus estimate for TransMedics Group’s current full-year earnings is $1.00 per share.

Other research analysts also recently issued reports about the company. Morgan Stanley lifted their price objective on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Canaccord Genuity Group reissued a “buy” rating and issued a $142.00 price target on shares of TransMedics Group in a report on Tuesday, October 14th. Zacks Research downgraded TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Evercore ISI initiated coverage on TransMedics Group in a research note on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price objective on the stock. Finally, Jefferies Financial Group began coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 target price for the company. Eight research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average target price of $130.73.

TransMedics Group Stock Performance

Shares of TMDX opened at $132.45 on Monday. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $145.50. The stock has a market cap of $4.52 billion, a P/E ratio of 68.63 and a beta of 2.08. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The company has a 50-day moving average of $116.08 and a two-hundred day moving average of $116.24.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm had revenue of $157.37 million for the quarter, compared to analysts’ expectations of $146.64 million. During the same period in the prior year, the company earned $0.35 EPS. The firm’s revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS.

Institutional Trading of TransMedics Group

A number of hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its stake in shares of TransMedics Group by 551.7% during the 1st quarter. GAMMA Investing LLC now owns 1,564 shares of the company’s stock valued at $105,000 after acquiring an additional 1,324 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in TransMedics Group by 129.9% in the first quarter. Janney Montgomery Scott LLC now owns 8,799 shares of the company’s stock valued at $592,000 after purchasing an additional 4,972 shares during the period. Cambridge Investment Research Advisors Inc. increased its position in TransMedics Group by 65.9% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 11,692 shares of the company’s stock worth $787,000 after purchasing an additional 4,643 shares during the last quarter. Perigon Wealth Management LLC raised its stake in TransMedics Group by 31.8% during the first quarter. Perigon Wealth Management LLC now owns 18,820 shares of the company’s stock worth $1,266,000 after purchasing an additional 4,543 shares during the period. Finally, Lisanti Capital Growth LLC acquired a new position in shares of TransMedics Group in the 1st quarter valued at $1,942,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.